RZLT · CIK 1509261
What Rezolute, Inc. told the SEC could break it.
2 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
A limited set so far, we surface every cited disclosure we’ve extracted for RZLT. More may follow as additional filings are processed.
In its own words
What could break it.
Liquidity & debt
- Pre-revenue capital dependence and contingent milestone obligationsmedium
Rezolute is a clinical-stage company with no product revenue and depends on raising additional financing; it also carries contingent milestone obligations of $25M to XOMA and up to $25M to ActiveSite on ersodetug.
“regulatory milestone payment of $25.0 million payable to XOMA and additional clinical and regulatory milestone payments up to $25.0 million payable to ActiveSite.”
SEC filing →As of 2025
Supplier concentration
- Reliance on third-party manufacturers for clinical and commercial supplymedium
Rezolute has no commercial-scale manufacturing experience and must rely on third-party manufacturers to scale production to meet projected commercial needs, which may not be met on a timely basis.
“We have no experience manufacturing pharmaceutical products on a commercial scale and we may need to rely on third-party manufacturers with capacity for increased production scale to meet our projected needs for commercial manufacturing, the satisfaction of which on a timely basis may not be met.”
SEC filing →As of 2025
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Handok Inc.
“the Company will sell products ordered by Handok at a transfer price equal to 70 % of the net selling price of the products.”
Cited →
Its suppliers
ActiveSite Pharmaceuticals
“regulatory milestone payment of $25.0 million payable to XOMA and additional clinical and regulatory milestone payments up to $25.0 million payable to ActiveSite.”
Cited →“regulatory milestone payment of $25.0 million payable to XOMA and additional clinical and regulatory milestone payments up to $25.0 million payable to ActiveSite.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch